CPT 81456: RNA Genomic Sequence Analysis Panel, 51+ Genes
CPT code 81456 represents a comprehensive RNA-based genomic sequence analysis panel that evaluates 51 or more genes for alterations relevant to solid organ cancers and hematolymphoid disorders. This high-complexity molecular test supports diagnostic characterization, prognostic assessment, and potential therapeutic targeting in oncology. As precision oncology expands, such multi-gene RNA panels have become clinically significant for identifying actionable alterations and informing treatment selection.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage considerations across major commercial payers and Medicare, comparisons to related genomic testing codes, and clinical context regarding specimen types (tumor tissue or bone marrow) and laboratory-based service settings. The publication highlights billing and coding implications for high-complexity molecular diagnostics, common clinical indications tied to solid organ neoplasms, and the role of RNA panels alongside DNA-based testing. The analysis also outlines benchmarking and policy topics relevant to nationwide payer practices and the operational impact for laboratories and pathology services.
Customize your policy alerts
Sign up for cpt 81456 policy alerts
Get alerted when payer policies referencing 81456 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 81456 describes a genomic sequence analysis panel performed on a patient specimen to evaluate RNA alterations in 51 or more genes associated with solid organ cancers or hematolymphoid (blood or lymph) disorders and cancers. The procedure involves laboratory analysis of nucleic acids (RNA) to identify sequence-level changes across a broad panel of genes relevant to oncology.
Service Type: Genomic sequence analysis (RNA panel)
Typical Site of Service: Clinical laboratory or hospital pathology/laboratory setting, using tumor tissue or bone marrow specimens collected in an appropriate clinical environment.
National Reimbursement Benchmarks
National commercial reimbursement for CPT 81456 centers near the BUCA average commercial rate of $2,715.70, with notable divergence across major carriers. Blue Cross Blue Shield shows the highest dispersion between its 25th and 75th percentiles (range $1,527.8: $3,620.20 minus $2,092.40 = $1,527.80), indicating broader variability in negotiated rates. Cigna and Aetna also display substantial spreads (Cigna P75–P25 = $2,001.80; Aetna P75–P25 = $914.40), while UnitedHealth Group presents a more compressed interquartile spread of $1,693.40.
Examining central tendency, Cigna and Blue Cross Blue Shield have higher median and mean points relative to UnitedHealth Group, which records a lower median of $1,751.80 and a mean of $2,324.10. BUCA’s mean of $2,715.70 aligns with the upper-middle marketplace position. Overall, dispersion patterns suggest Blue Cross Blue Shield and Cigna offer the widest rate variability, while UnitedHealth Group is comparatively tighter.